News

Tafamidis (Vyndaqel/Vyndamax) stabilizes transthyretin (TTR) tetramer, preventing amyloidogenesis. It is the only approved disease-modifying therapy in ATTR…

Patisiran (Onpattro) and inotersen (Tegsedi) are TTR mRNA silencing therapies in hereditary ATTR amyloidosis (hATTR). Patisiran is lipid nanoparticle RNAi (siRNA),…

Acoramidis provides consistent clinical benefit in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) irrespective of baseline atrial…

AbstractBackgroundAdvances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but…

AbstractIntroduction and objectives: To describe the clinical characteristics of patients with cardiac amyloidosis who have undergone heart transplantation (HT).…

Background: Transthyretin amyloidosis (ATTR) is an underdiagnosed cause of cardiomyopathy that is gaining recognition as new treatments become available. The…

The incidence and prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) increased markedly in the US between 2010 and 2023, according to a study published in…

Cardiac amyloidosis is a condition in which abnormal proteins, called amyloid, build up in the heart muscle. Over time, these deposits make the heart walls stiffer…

A computerized test that measures how quickly and accurately people perform finger tapping and hand movement tasks was able to detect subtle motor problems in…

AbstractPurposeTo provide an overview of the manifestation and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and the treatment option acoramidis,…